#SGOmtg Twitter Highlights - Research Highlights Sunday March 25, 2018

Sunday was another busy day of information sharing at the SGO Annual Meeting in New Orleans.
Here are the topics that caught my eye while following the #SGOmtg hashtag.

Ovarian Cancer Maintenance Rucaparib - NOVA Study

#NOVA retrospective data show low wt & low baseline platelets associated w/ increased risk of Gr.3/4 thrombocytopenia w/ maintenance #rucaparib for #ovariancancer. #SGOmtg #gyncsm pic.twitter.com/JqSwALqoKR

— Deanna Teoh, M.D. (@DeannaTeoh) March 25, 2018

Ovarian Cancer - Niraparib and Cost effectiveness

#Niraparib maintenance for #ovariancancer not #costeffective unless drug cost drastically reduced. Need to advocate for #DecreasedDrugCosts. #SGOmtg #gyncsm pic.twitter.com/qwbGelJYgG

— Deanna Teoh, M.D. (@DeannaTeoh) March 25, 2018

Ovarian Cancer - Parp inhibitor and BRCA status

Beautiful study demonstrating higher value of #PARPi for #BRCA mutant #ovariancancer compared to wild type. It is important to consider #PrecisionMedicine when making treatment decisions. #SGOMtg #gyncsm pic.twitter.com/tgyvD5i4Dk

— Shannon Westin (@ShannonWestin) March 25, 2018

Endometrial Cancer GOG 86 P Predictive biomarkers of endometrial cancer

Slides for today’s #SGOmtg GOG-86P translational science presentation are available at: https://t.co/dXapOLGXce

— Douglas Levine MD (@levinemd) March 25, 2018

Endometrial Cancer PORTEC3

PORTEC 3: in chemo/RT vs RT, role in stage III, balance with toxicity. So many exciting results coming out at #SGOMtg #gyncsm #endometrialcancer pic.twitter.com/n6a58Vy71t

— Jolyn Taylor (@TaylorJolyn) March 25, 2018

PORTEC3: ChemoRT vs RT alone: 5y FFS 76v69% (sig) 5yOS 82v77% (NS) #SGOMtg (H/T @stigetta)

— Don S Dizon (@drdonsdizon) March 25, 2018

Endometrial - GOG 249

Dr. Marcus Randall discussing GOG 249 results: pelvic RT vs chemo/brachy similar RFS and OS; more acute toxicity in chemo arm, similar late tox #SGOMtg #gyncsm #endometrialcancer pic.twitter.com/cT4zbjoUbc

— Jolyn Taylor (@TaylorJolyn) March 25, 2018

Cervical Cancer - chemo /radiation

Improved DFI but not OS in locally advanced cervical cancer itrated with chemo/RT as compared to neoadjuvant chemo followed by surgery. Recommend chemo/Rt #SGOMtg pic.twitter.com/3AhvmPAUcR

— Rick Boulay,MD (@journeycancer) March 25, 2018

Thank you to Rick Boulay,MD, Jolyn Taylor, Don S Dizon, Douglas Levine MD,  Shannon Westin and Deanna Teoh, M.D. for tweeting using the #SGOmtg hashtag so those of us following from a distance can learn.


Dee
Every Day is a Blessing!